Key facts
- Amprologix’s last known valuation is $10.9M (Oct 2025).
- It has raised $1.0M.
- Notable investors include MassChallenge, UK Research and Innovation, Plutus Investment Group, Ingenza, University of Plymouth.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Amprologix
- ·The full record, as it builds
Funding rounds
No funding rounds for Amprologix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amprologix
Developer of antimicrobial-resistant drugs designed to combat drug-resistant infections. The company utilizes cutting-edge machine learning algorithms to improve antibiotic properties, including nasal decolonization of methicillin-resistant Staphylococcus aureus, pneumonia, and surface skin infections, enabling clients to combat the growing problem of antibiotic resistance.
- Sector
- Healthcare
- HQ
- Plymouth, United Kingdom
- Founded
- 2018
- Employees
- 4
- Website
- amprologix.com/
- Ownership
- Privately Held (backing)
Amprologix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amprologix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amprologix in its N-PORT filings yet. We sweep new filings monthly.